Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InnerPulse Inc.
Boston Scientific’s S-ICD subcutaneous implantable cardioverter defibrillator performed well in the EFFORTLESS registry, with clinical event rates and inappropriate shock rates similar to those reported for conventional ICDs in a real-world context.
A percutaneous intravascular cardioverter-defibrillator matched a conventional ICD in a randomized comparison of defibrillation thresholds. The authors of the study believe the PICD could reduce many of the complications associated with conventional defibrillators.
At Elsevier Business Intelligence's February IN3 West conference, a panel of leading device venture investors, who remain committed to and are actively doing deals in medtech, discussed how the recent recession has affected device investing and how much, if at all, that world has changed as a result.
Welsh, Carson, Anderson & Stowe, a long time investor in health care services companies, signaled its intent to invest more deeply in the device sector with the acquisition of a majority position in spinal company K2M Inc.
- Implantable Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.